Liranaftate and mometasone furoate containing locally applied compound pharmaceutical composition

A technology for topical application of mometasone furoate, applied in the direction of drug combinations, medical preparations containing active ingredients, local antibacterial agents, etc., can solve the problems of obvious, easy to relapse, and ineffective curative effect

Active Publication Date: 2012-03-21
南昌百济制药有限公司
View PDF4 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] At present, liranaftate and mometasone furoate only have single preparations, and the dosage forms are mainly cream and gel. They have the disadvantage of ineffective efficacy for skin diseases with both fungal infections and inflammatory reactions.
CN101108184 discloses a compound preparation composed of liranaftate and dexamethasone, but dexamethasone is a fluorine-containing glucocorticosteroid, and local application has strong skin dependence, and drug withdrawal is easy to relapse, and the side effects are skin thinning and atrophy obvious

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Liranaftate and mometasone furoate containing locally applied compound pharmaceutical composition
  • Liranaftate and mometasone furoate containing locally applied compound pharmaceutical composition
  • Liranaftate and mometasone furoate containing locally applied compound pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Embodiment 1, compound recipe liranaftate mometasone furoate cream

[0044] formula:

[0045] Main ingredients: liranaftate 0.5g, mometasone furoate 20g

[0046] Oil phase: 10g beeswax, 70g light liquid paraffin

[0047] Emulsifier: Cetearyl Alcohol 90g, Glyceryl Monostearate 15g, Sodium Lauryl Sulfate 10g

[0048] Preservatives: Ethylparaben 1g,

[0049] Water phase: propylene glycol 50g, distilled water 733.5ml

[0050] Preparation method: take cetearyl / stearyl alcohol, glyceryl monostearate, beeswax, light liquid paraffin, ethylparaben, and heat to dissolve into an oil phase. Separately take propylene glycol and distilled water and heat to 90°C, then add sodium lauryl sulfate to dissolve into water phase. Then slowly pour the water phase into the oil phase, and stir while adding until it cools down to obtain an emulsion matrix. Add liranaftate and mometasone furoate into the above matrix, and stir while adding until uniform, that is be made of.

Embodiment 2

[0051] Embodiment 2, compound recipe liranaftate mometasone furoate gel

[0052] formula:

[0053] Main ingredients: liranaftate 0.5g, mometasone furoate 20g

[0054] Gel base: Carbomer 12g

[0055] Complexing agent: Edetate disodium 0.5g

[0056] Preservative: Ethylparaben 2g

[0057] pH adjuster: Triethanolamine 7g

[0058] Water phase: propylene glycol 150g, ethanol 100g, distilled water 708ml

[0059] Preparation method: Sprinkle a small amount of carbomer into the aqueous solution of disodium ethylenediamine tetraacetate and propylene glycol under stirring. After it is completely dissolved, add triethanolamine solution and stir, then add liranaphthyl ester and molybdenum furoate Ethanol solution of metasone and ethylparaben. Mix well and serve.

Embodiment 3

[0060] Embodiment 3, compound recipe liranaftate mometasone furoate suspension

[0061] formula:

[0062] Main ingredients: liranaftate 20g, mometasone furoate 0.5g

[0063] Wetting agent: glycerin 200g

[0064] Suspending agent: sodium carboxymethylcellulose 5g

[0065] Solvent: water 775ml;

[0066] Preparation method: Liranaftate and mometasone furoate are ground into a paste with glycerin, and sodium carboxymethylcellulose is made into a paste, mixed with glycerin paste under stirring, added water to the full amount, and stirred evenly, that is have to.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of antimycotic medicaments, specifically to a liranaftate and mometasone furoate containing locally applied compound pharmaceutical composition, which contains one or more acceptable auxiliary materials for local application. The invention is characterized in that the weight ratio of liranaftate to mometasone furoate is 1:80-80:1; the balance contains matrix auxiliary materials; The pharmaceutical composition can be emulsifiable paste or ointment, gelata, a solution or an emulsion or a suspension, a coating agent, aerosol or a spraying agent or spray-film, a foaming agent and patch. With the application of the liranaftate and mometasone furoate compound pharmaceutical composition, as mometasone furoate has a vasoconstriction effect, the transdermal absorption rate of liranaftate slows down, local skin tissue concentration of liranaftate is increased, the medicament is minimized to penetrate through the skin into blood, and local skin concentration of the antimycotic medicament is maintained for a longer time.

Description

[technical field] [0001] The patent of the present invention relates to the technical field of antifungal drugs, specifically a compound pharmaceutical composition for local application containing liranaftate and mometasone furoate. [Background technique] [0002] Fungi are usually conditional pathogens for healthy humans, but when the body's resistance is reduced and external factors are unfavorable, they may cause systemic or local fungal infections. Clinically, they are divided into superficial fungal infections and deep fungal infections. [0003] Superficial fungi mainly refer to dermatophyton, including trichophyton, microsporum and epidermophyton. Skin, hair, deck, the infection that causes is collectively referred to as dermatophytosis (dermatophytosis), abbreviated tinea (tinea), can be divided into several categories such as tinea capitis, tinea corporis, tinea manuum and tinea unguium according to the affected part. Dermatophytosis is the most common superficial ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/58A61K31/44A61P31/02A61P31/10A61P17/00
Inventor 沈冬冬刘军
Owner 南昌百济制药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap